Liquid biopsy for monitoring pancreatic cancer after surgery
Part of Cancer clinical trials.
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic ductal adenocarcinoma (PDAC).
- Your doctor plans to remove the tumor with surgery aimed at curing the cancer.
- The cancer has not spread to distant organs (no distant metastases).
- You have not had another cancer (except for prior pancreatic cancer or non-melanoma skin cancer) in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple blood test (liquid biopsy) to look for tiny bits of cancer DNA after surgery for colorectal cancer that spread to the liver. It aims to see if this test can find cancer earlier than standard scans, which may help guide future treatment decisions.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This study is testing a way to use blood samples, called liquid biopsies, to find tiny bits of cancer left after surgery and choose the best follow-up treatments for pancreatic cancer. It might help doctors personalize care for each patient.
This trial uses a liquid biopsy (a simple blood test that looks for cancer DNA) to decide whether you should have chemotherapy before surgery or go straight to surgery. It is for people with pancreatic cancer that has not spread beyond the pancreas.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.